Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 30, 2020
Current assets:
Cash and cash equivalents	$ 9,216,349	$ 593,869
Short-term investments	233,642	0
Accounts receivable	144,244	0
Due from subsidiary	0	329,330
Prepaid expenses	2,688,472	0
Other current assets	1,045,332	2,547
Total current assets	13,328,039	925,746
Non-current assets:
Operating lease right-of-use assets	840,590	101,048
Restricted cash	5,000,000	0
Goodwill	76,972,668	0
Intangible assets, net	1,575,278	0
Property and equipment, net	119,133	8,690
Contract asset	192,222	0
Total non-current assets	84,699,891	109,738
Assets of discontinued operation	8,123
Total assets	98,036,053	1,035,484
Current liabilities:
Accounts payable and accrued expenses	5,928,805	2,687,847
Current portion of operating lease liabilities	198,302	30,758
Deferred revenue	506,032	0
Stock issuances due	470,828	0
Notes payable	2,883,333	1,902,237
Advances from related party	200,000	0
Total current liabilities	10,187,300	4,620,842
Operating lease liabilities, net of current portion	737,403	70,380
Long-term debt	12,916,667	0
Total long-term liabilities	13,654,070	70,380
Liabilities of discontinued operation	63	0
Total liabilities	23,841,433	4,691,222
Stockholders’ equity (deficit):
Preferred stock, $.005 par value; 1,000,000 shares authorized as of September 30, 2021 and December 31, 2020; 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020	0	0
Common stock, $.005 par value; 150,000,000 shares authorized as of September 30, 2021 and 25,000,000 shares authorized as of December 31, 2020; 32,095,520 shares issued and outstanding as of September 30, 2021 and 13,376,062 shares issued and outstanding as of December 31, 2020	160,478	160,478
Additional paid-in capital	126,220,319	23,946,747
Accumulated other comprehensive loss	(2,014)	0
Accumulated deficit	(52,256,361)	(27,762,963)
Total Statera Biopharma, Inc. stockholders’ equity (deficit)	74,122,422	(3,655,738)
Noncontrolling interest in stockholders’ equity	72,198	0
Total stockholders’ equity (deficit)	74,194,620	(3,655,738)
Total liabilities and stockholders’ equity	$ 98,036,053	$ 1,035,484